Pharmaceuticals

CytoReason’s technology uses a machine learning model to build a molecular level understanding of tissues in diseases on the cellular level.

The study is expected to include about 120 sites globally and could include up to 30,000 participants. It will include regions heavily impacted by COVID-19.

If it receives marketing approval, the companies are preparing to make up to 100 million doses by the end of 2020 and another 1.2 billion doses by the end of 2021.

"These first trial results show that the vaccine yields immune activity and causes a strong immune response," said BioNTech's co-founder and Chief Executive Officer Ugur Sahin.

The company has developed a unique method of creating a vaccine by letting plants do the work. "We're using plants as mini factories," said Natalie Charland, a senior director at Medicago.

The new method of testing bypasses many tedious screening methods, making it faster, cheaper and more efficient.

A number of Super Pharm’s managers attended the ceremony, and Kupler and Keshet arranged to meet again in the future to discuss continued cooperation.

Teva completed its two-year major restructuring plan in 2019, reducing its cost base by over $3 billion and net debt by more than $9b.

When it comes to being excited by experiments, age is simply not a factor for 86-year-old Prof. Ruth Arnon, co-creator of multiple sclerosis drug Copaxone.

Researcher Hila Flayev has for years been conducting research on computational models of the coronavirus structure and interactions it can create.